Results 121 to 130 of about 852 (150)
Treatment of Homozygous Familial Hypercholesterolemia With ANGPTL3 Inhibitor, Evinacumab
JCEM Case Reports, 2023 Abstract Homozygous familial hypercholesterolemia (HoFH) is an ultra-rare, life-threatening, genetic condition characterized by markedly elevated levels of low-density lipoprotein cholesterol (LDL-C). Standard lipid-lowering therapies minimally reduce LDL-C in these patients, and lifelong serial apheresis is the mainstay of treatment ...
, Robert Hegele, Mccrindle Brian W
exaly +3 more sources
Individualized dosing of evinacumab is predicted to yield reductions in drug expenses [PDF]
Journal of Clinical Lipidology, 2023 Evinacumab is a first-in-class inhibitor of angiopoietin-like protein 3 (ANGPTL3) for treatment of the rare disease homozygous familial hypercholesterolemia (HoFH). With projected drug costs of $450,000 per person per year, the question rises if cost-efficacy of evinacumab can be further improved.To develop an individualized dosing regimen te reduce ...
Jeanine Roeters Van Lennep +2 more
exaly +4 more sources
Evinacumab for Pediatric Patients With Homozygous Familial Hypercholesterolemia
CirculationBACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare genetic disorder characterized by severely elevated low-density lipoprotein cholesterol (LDL-C) levels due to profoundly defective LDL receptor (LDLR) function.
Albert Wiegman +2 more
exaly +4 more sources
JACC: Advances, 2023 Homozygous familial hypercholesterolemia (HoFH) is characterized by early-onset atherosclerotic cardiovascular disease due to the high low-density lipoprotein cholesterol (LDL-C) burden. Patients with null-null low-density lipoprotein receptor (LDLR) variants respond poorly, if at all, to statins and proprotein convertase subtilisin/kexin type 9 ...
Erik Stroes, , Laurens Reeskamp
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs, 2021
The recombinant human monoclonal antibody evinacumab (evinacumab-dgnb, EVKEEZA™) is an angiopoietin-like protein three (ANGPTL3) inhibitor that has been developed by Regeneron Pharmaceuticals for the treatment of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolemia (both familial and non-familial) and severe ...
openaire +2 more sources
The recombinant human monoclonal antibody evinacumab (evinacumab-dgnb, EVKEEZA™) is an angiopoietin-like protein three (ANGPTL3) inhibitor that has been developed by Regeneron Pharmaceuticals for the treatment of homozygous familial hypercholesterolaemia (HoFH), refractory hypercholesterolemia (both familial and non-familial) and severe ...
openaire +2 more sources
Evinacumab: a new option in the treatment of homozygous familial hypercholesterolemia
Expert Opinion on Biological Therapy, 2022Familial hypercholesterolemia is a genetic disorder characterized by elevated levels of low-density lipoprotein cholesterol (LDL-C) since birth and an exceedingly high risk of premature cardiovascular disease, especially in the homozygous form (HoFH). Despite the availability of effective cholesterol-lowering drugs, substantial LDL-C and cardiovascular
Angela, Pirillo, Alberico L, Catapano
openaire +2 more sources
Efficacy and Safety of Evinacumab for the Treatment of Hypercholesterolemia: A Meta-Analysis
Journal of Cardiovascular Pharmacology, 2021Abstract: Angiopoietin-like protein 3 is essential in lipid metabolism regulation. However, the efficacy and safety of evinacumab (angiopoietin-like protein 3 inhibition drug) for hypercholesterolemia treatment is unknown. In this study, a meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of ...
Menglong, Jin +5 more
openaire +2 more sources
Canadian Journal of Health Technologies
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments ...
openaire +1 more source
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments ...
openaire +1 more source
Evinacumab for Homozygous Familial Hypercholesterolemia
New England Journal of Medicine, 2021Frederick J, Raal +2 more
openaire +5 more sources
Will evinacumab become the standard treatment for homozygous familial hypercholesterolemia?
Expert Opinion on Biological Therapy, 2020Introduction: Homozygous Familial Hypercholesterolemia (HoFH) is a very severe genetic form of hypercholesterolemia. Lacking LDL receptors in the liver, subjects with HoFH have raised plasma levels of LDL cholesterol, and up to 100 times higher risk of premature atherosclerotic cardiovascular disease than the general population.Areas covered: This ...
openaire +2 more sources